SGN-CD19B is an antibody-drug conjugate (ADC) targeted to CD19, a protein found broadly on B-cell hematologic malignancies. It uses our newest ADC technology, where the anti-CD19 antibody is attached with a stable linker to two molecules of a highly potent DNA crosslinking agent called a PBD (pyrrolobenzodiazepine) dimer.
This antibody-drug conjugate (ADC) is designed to be stable in the bloodstream, and to release its cytotoxic agent once inside the CD19-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.
Phase 1 trial evaluating safety and antitumor activity of SGN-CD19B in patients with B-cell non-Hodgkin lymphoma.